'UrGenT' and 'CardioGenix': The early development of two German Biotech ventures, and the impact of venture capitalists and the financial markets on them: European Case Study no 4/5, Gate 2 Growth project, European Commission, 2004

Robert Cressy, S Remer

    Research output: Other contribution

    Original languageEnglish
    TypeOther Contribution
    Publication statusPublished - 1 Jan 2004

    Cite this